AVTE News and Press, Aerovate Therapeutics Inc.

2024-07-08 08:26:56 ET More on Aerovate Therapeutics Aerovate: Imatinib Delivery Change Leads To Targeting Of Massive PAH Market Aerovate Therapeutics slides after its hypertension treatment fails to meet main goal Read the full article on Seeking Alpha For f...

WALTHAM, Mass., July 08, 2024 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), which previously announced it was halting enrollment and shutting down the Phase 3 portion of the I nhaled i M atinib P ulmonary A rterial H ypertension C linical T rial (IMPA...

2024-06-27 07:00:00 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Wall Street’s leading analysts have been adjusting their S&P 500 forecasts in recent days. Driven by potential Federal Reserve interest rate cuts, strong performance from lar...

A look at the top 10 most actives in the United States Mustang Bio Inc. (MBIO) rose 476.9% to $0.75 on volume of 1,104,730,765 shares NVIDIA Corporation (NVDA) fell 0.7% to $130.98 on volume of 283,604,651 shares ENDRA Life Sciences Inc. (NDRA) rose 34.2% to $0.139 on volume of 219,783,92...

A look at the top 10 most actives in the United States Mustang Bio Inc. (MBIO) rose 141.4% to $0.3138 on volume of 161,736,322 shares ENDRA Life Sciences Inc. (NDRA) rose 13.7% to $0.117778 on volume of 79,058,950 shares AgriFORCE Growing Systems Ltd. (AGRI) rose 27.2% to $0.1042 on volum...

2024-06-17 09:22:41 ET More on Aerovate Therapeutics Aerovate: Imatinib Delivery Change Leads To Targeting Of Massive PAH Market Seeking Alpha’s Quant Rating on Aerovate Therapeutics Historical earnings data for Aerovate Therapeutics Financial informat...

WALTHAM, Mass., June 17, 2024 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE) today announced topline results from the Phase 2b portion of the I nhaled i M atinib P ulmonary A rterial H ypertension C linical T rial (IMPAHCT), a Phase 2b/Phase 3, randomiz...

2024-06-11 13:19:13 ET Summary Aerovate Therapeutics, Inc. results from the phase 2 portion of the phase 3 IMPAHCT trial, using AV-101 for the treatment of patients with pulmonary arterial hypertension, expected in June 2024. The global Pulmonary Arterial Hypertension market size ...

2024-06-11 06:46:36 ET More on Golden Heaven Group Holdings Financial information for Golden Heaven Group Holdings Read the full article on Seeking Alpha For further details see: Aerovate Therapeutics files for $350M mixed securities shelf

2024-06-09 23:50:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...